Abstract:Introduction Accumulation of senescent cells is observed in various organs including vasculature, heart and white adipose tissue with age, and known to become a substrate of pathophysiology of various cardiovascular-metabolic diseases. We have previously developed a vaccine to eliminate senescent cells, so-called "senolytic vaccine" by targeting Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) as a cellular-senescence-associated cell surface protein. We have demonstrated that GPNMB senolytic vaccine could remove senescent cells and alleviate the pathology cardiovascular-metabolic diseases. Senescence-associated adhesion molecule 1 (SAAM-1) is also known as a cell-surface membrane to increase its expression during cellular senescence in endothelial cells as well as the development of cardiovascular diseases. Here, we identified SAAM-1 as another senescence antigen and created a vaccine to eliminate senescent cells by targeting SAAM-1. Purpose This study was purposed to evaluate the efficacy of SAAM-1 vaccine for the treatment of cardiovascular diseases in mice models. Methods As a pressure overload-induced heart failure (HF) model, C57BL/6N wild type (WT) mice were underwent transverse aortic constriction (TAC) or sham opretaion at 13 weeks of age. SAAM-1 or control vaccination were given at 8 and 10 weeks of age before operation. Echocardiography examination was conducted two weeks after TAC operation, followed by tissue sampling 3 weeks after the examination. As an atherosclerosis model, ApoE KO mice were subjected to a high-fat diet (HFD) starting at 4 weeks of age. Vaccination of ApoE KO mice was administered at 8 weeks of age with SAAM-1-vaccine or control-vaccine, followed by sacrifice 4 weeks later for further analysis. ApoE-KO mice were also crossed with p16-mediated Luciferase expressing mice (p16-Luc mice) and subjected to generation of atherosclerosis model. Results SAAM-1 expression was significantly increased in left ventricle (LV) in TAC mice but its increase was suppressed by SAAM-1 vaccination. Interestingly, both worsening systolic function and dilatation of LV by pressure overload were significantly alleviated by SAAM-1 vaccination. Furthermore, expression level of senescent markers including p16 and p21, as well as several inflammation markers were increased in failing heart along with development of cardiac fibrosis, but SAAM-1 vaccine could significantly attenuate this pathological change. In ApoE KO mice, SAAM-1 vaccine decreased expression level of several inflammation markers in the mice, along with a decreasing p16 signal in the aorta. Conclusions Targeting SAAM-1 for vaccination would be a novel and promising approach to alleviating age-related cardiovascular disease.

COL6A6 Peptide Vaccine Alleviates Atherosclerosis through Inducing Immune Response and Regulating Lipid Metabolism in Apoe−/− Mice

VACCINATION AGAINST AGE-LDL SIGNIFICANT ATTENUATES ATHEROSCLEROSIS IN DIABETIC APOE MICE

Modulation of Recombinant Antigenic Constructs Containing Multi-Epitopes Towards Effective Reduction of Atherosclerotic Lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J Mice.

Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice.

Immunization with a combination of 2 peptides derived from the C5a receptor significantly reduces early atherosclerotic lesion in Ldlr(tm1Her) Apob(tm2Sgy) J mice.

Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

Abstract 154: Vaccination Using Advanced Glycation End Product of Low-Density Lipoprotein Pulsed Dendritic Cells Reduces Atherosclerosis in Diabetic Apoe <sup>-/-</sup> Mice

Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydophila pneumoniae on atherosclerotic lesion development in Apob(tm2Sgy)Ldlr(tm1Her)J mice.

Active immunization using TRPM2 peptide vaccine attenuates atherosclerotic progression in a mouse model of atherosclerosis

Immunization with Advanced Glycation End Products Modified Low Density Lipoprotein Inhibits Atherosclerosis Progression in Diabetic Apoe and LDLR Null Mice

Effects of Nasal Immunization of Multi-Target Preventive Vaccines on Atherosclerosis

Raising Endogenous Anti-HMGB1 IgM Antibody for Athero-Protection in the Apoe−/− Mouse Model of Atherosclerosis

Downregulation of G3BP2 Reduces Atherosclerotic Lesions in ApoE Mice

Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia

Apob-100 And Hsp60 Peptides Exert A Synergetic Role In Inhibiting Early Atherosclerosis In Immunized Apoe-Null Mice

Promotion of Atherosclerosis in High Cholesterol Diet-Fed Rabbits by Immunization with the P277 Peptide.

AtheroVax: a peptide vaccine with a therapeutic effect in animal model of chronic inflammation

Vaccine Targeting Alpha 1D-Adrenergic Receptor Improved Metabolic Syndrome in Mice

Vaccination targeting senescence-associated transmembrane protein alleviated cardiovascular pathology in the mice

Chronic Administration of Mitochondrion-Targeted Peptide Ss-31 Prevents Atherosclerotic Development in Apoe Knockout Mice Fed Western Diet

A Human Apolipoprotein E Mimetic Peptide Reduces Atherosclerosis in Aged Apolipoprotein E Null Mice.